Protective Effect of Eotaxin-2 Inhibition in Adjuvant-induced Arthritis

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2010 May 12

PMID 20456418

Citations 15

Authors

J N Ablin

M Entin-Meer

V Aloush

S Oren

O Elkayam

J George

I Barshack

Affiliations

Soon will be listed here.

Abstract

Eotaxin-2 is a potent chemoattractant for eosinophils, basophils and T helper type 2 (Th2) lymphocytes. The eotaxin-2/CCL24 receptor CCR3 is expressed in human brain, skin, endothelium and macrophages. The aim of the current study was to evaluate the protective effect of a monoclonal anti-eotaxin-2 antibody on the development of adjuvant-induced arthritis in rats (AIA). Adjuvant arthritis was induced in Lewis rats by intradermal injection of incomplete Freund's adjuvant +Mycobacterium tuberculosis. Rats were treated by intraperitoneal (i.p.) injection with three monoclonal antibodies against eotaxin-2 (G7, G8, D8) three times per week. Controls were treated with total mouse immunoglobulin G (IgG), methotrexate (MTX) or phosphate-buffered saline (PBS). Arthritis severity was evaluated by measuring ankle swelling, arthritic score, whole animal mobility and body weight. Sample joints were obtained for pathological evaluation and postmortem X-ray of ankle joints was performed to document erosions. Significant inhibition of arthritis was observed in rats treated with anti-eotaxin-2 antibodies compared to those treated with immunoglobulin or PBS. Inhibition was manifest in ankle diameter, arthritic score and mobility score. The antibody marked D8 showed the greatest efficacy. The effect was observed both in animals treated before the appearance of arthritis and in those where treatment was begun after development of joint inflammation. Combined treatment with D8 and MTX caused additional protection. Significant reduction of inflammation in D8-treated animals was also demonstrated in pathological and X-ray examinations. Inhibition of eotaxin-2 by monoclonal antibodies has a significant protective effect in adjuvant arthritis. These results may introduce a novel therapeutic target in rheumatoid arthritis and additional inflammatory joint disorders.

Citing Articles

The Role of CCL24 in Systemic Sclerosis.

Levy H, Gluschnaider U, Balbir-Gurman A Rambam Maimonides Med J. 2023; 14(3).

PMID: 37555717 PMC: 10393469. DOI: 10.5041/RMMJ.10504.

Chemokines and chemokine receptors as promising targets in rheumatoid arthritis.

Murayama M, Shimizu J, Miyabe C, Yudo K, Miyabe Y Front Immunol. 2023; 14:1100869.

PMID: 36860872 PMC: 9968812. DOI: 10.3389/fimmu.2023.1100869.

G-Protein-Coupled Receptors in Rheumatoid Arthritis: Recent Insights into Mechanisms and Functional Roles.

Zhao J, Wei K, Jiang P, Chang C, Xu L, Xu L Front Immunol. 2022; 13:907733.

PMID: 35874704 PMC: 9304905. DOI: 10.3389/fimmu.2022.907733.

Dissecting the cellular landscape and transcriptome network in viral myocarditis by single-cell RNA sequencing.

Lasrado N, Borcherding N, Arumugam R, Starr T, Reddy J iScience. 2022; 25(3):103865.

PMID: 35243228 PMC: 8861636. DOI: 10.1016/j.isci.2022.103865.

CCL24 Signaling in the Tumor Microenvironment.

Lim S Adv Exp Med Biol. 2021; 1302:91-98.

PMID: 34286443 DOI: 10.1007/978-3-030-62658-7_7.

References

Ponath P, Qin S, Ringler D, Clark-Lewis I, Wang J, Kassam N . Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996; 97(3):604-12. PMC: 507095. DOI: 10.1172/JCI118456. View

Sallusto F, Lenig D, Mackay C, Lanzavecchia A . Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998; 187(6):875-83. PMC: 2212187. DOI: 10.1084/jem.187.6.875. View

Viola A, Luster A . Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2007; 48:171-97. DOI: 10.1146/annurev.pharmtox.48.121806.154841. View

Simpson J, Rezaie P, Newcombe J, Cuzner M, Male D, Woodroofe M . Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol. 2000; 108(1-2):192-200. DOI: 10.1016/s0165-5728(00)00274-5. View

Zimmerman N, Vongsa R, Wendt M, Dwinell M . Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14(7):1000-11. PMC: 4114077. DOI: 10.1002/ibd.20480. View

Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M . Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest. 2001; 107(1):53-63. PMC: 198541. DOI: 10.1172/JCI9775. View

Elsner J, Petering H, Kluthe C, Kimmig D, Smolarski R, Ponath P . Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur J Immunol. 1998; 28(7):2152-8. DOI: 10.1002/(SICI)1521-4141(199807)28:07<2152::AID-IMMU2152>3.0.CO;2-G. View

Beaulieu S, Robbiani D, Du X, Rodrigues E, Ignatius R, Wei Y . Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells. J Immunol. 2002; 169(6):2925-36. DOI: 10.4049/jimmunol.169.6.2925. View

Uguccioni M, Mackay C, Ochensberger B, Loetscher P, Rhis S, LaRosa G . High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest. 1997; 100(5):1137-43. PMC: 508288. DOI: 10.1172/JCI119624. View

10.

Shahrara S, Proudfoot A, Woods J, Ruth J, Amin M, Park C . Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. 2005; 52(6):1907-19. PMC: 1282452. DOI: 10.1002/art.21033. View

11.

Garcia G, Godot V, Humbert M . New chemokine targets for asthma therapy. Curr Allergy Asthma Rep. 2005; 5(2):155-60. DOI: 10.1007/s11882-005-0090-0. View

12.

Tachimoto H, Kikuchi M, Hudson S, Bickel C, Hamilton R, Bochner B . Eotaxin-2 alters eosinophil integrin function via mitogen-activated protein kinases. Am J Respir Cell Mol Biol. 2002; 26(6):645-9. DOI: 10.1165/ajrcmb.26.6.4741. View

13.

Guglielmotti A, DOnofrio E, Coletta I, Aquilini L, Milanese C, Pinza M . Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production. Inflamm Res. 2002; 51(5):252-8. DOI: 10.1007/pl00000301. View

14.

de Jager W, Hoppenreijs E, Wulffraat N, Wedderburn L, Kuis W, Prakken B . Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2006; 66(5):589-98. PMC: 1954617. DOI: 10.1136/ard.2006.061853. View

15.

Romagnani P, De Paulis A, Beltrame C, Annunziato F, Dente V, Maggi E . Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol. 1999; 155(4):1195-204. PMC: 1867029. DOI: 10.1016/S0002-9440(10)65222-4. View

16.

Haringman J, Smeets T, Reinders-Blankert P, Tak P . Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis. 2005; 65(3):294-300. PMC: 1798063. DOI: 10.1136/ard.2005.037176. View

17.

Firestein G . Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937):356-61. DOI: 10.1038/nature01661. View

18.

Arend W . Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum. 2001; 45(1):101-6. DOI: 10.1002/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7. View

19.

Tachimoto H, Burdick M, Hudson S, Kikuchi M, Konstantopoulos K, Bochner B . CCR3-active chemokines promote rapid detachment of eosinophils from VCAM-1 in vitro. J Immunol. 2000; 165(5):2748-54. DOI: 10.4049/jimmunol.165.5.2748. View

20.

Ying S, Robinson D, Meng Q, Barata L, McEUEN A, Buckley M . C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and.... J Immunol. 1999; 163(7):3976-84. View